MiRNA-based therapy for pulmonary arterial hypertension: MiRNA-28 inhibits the development of pulmonary arterial hypertension via down regulation of its target gene, 21/January/2014, 19.27

MiRNA-based therapy for Pulmonary Hypertension: MiRNA-302b inhibits pulmonary hypertension via down regulation of its target genes, 21/January/2015, 19.05
January 21, 2015
Natural product-based therapy for pulmonary arterial hypertension: Baicalein (5,6,7-Trihydroxyflavone), an active component of Scutellaria baicalensis, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene, 22/November/2014, 5.50 am
January 22, 2015
Show all

A study from the University of California, La Jolla, CA, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November  2009 issue of Nature Medicine by Prof. Thistlethwaite PA, Li X and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based therapy for pulmonary arterial hypertension: MiRNA-28 inhibits the development of pulmonary arterial hypertension via down regulation of its target gene. Together, pharmacological formulations encompassing “MiRNA-28 activators” may be used to treat pulmonary arterial hypertension.

Amount: $ 500

Undisclosed information: How MiR-28 decreases pulmonary arterial hypertension

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, MiRNA-based therapy for pulmonary arterial hypertension: MiRNA-28 inhibits the development of pulmonary arterial hypertension via down regulation of its target gene, 21/January/2014,  19.27,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Comments are closed.